Literature DB >> 17409425

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Suresh M Kumar1, Hong Yu, Robin Edwards, Lianjun Chen, Steven Kazianis, Patricia Brafford, Geza Acs, Meenhard Herlyn, Xiaowei Xu.   

Abstract

Mutations in the BRAF serine/threonine kinase gene are frequently found in cutaneous melanomas. Activation of hypoxia inducible factor-1alpha (HIF-1alpha) in response to both hypoxic stress and oncogenic signals has important implications in cancer development and progression. Here, we report that mutant BRAF(V600E) increases HIF-1alpha expression in melanoma cells. Our microarray profiling data in 35 melanoma and melanocyte cell lines showed that HIF-1alpha gene expression was significantly increased in melanomas harboring BRAF(V600E) mutation. Stable suppression of mutant BRAF(V600E) or both wild-type and mutant BRAF(V600E) by RNA interference in melanoma cells resulted in significantly decreased HIF-1alpha expression. Knockdown of mutant BRAF(V600E) induced significant reduction of cell survival and proliferation under hypoxic conditions, whereas knockdown of both wild-type and mutant BRAF(V600E) resulted in further reduction. The effects of BRAF knockdown can be rescued by reintroducing BRAF(V600E) into tumor cells. Transfection of BRAF(V600E) into melanoma cells with wild-type BRAF induced significantly more hypoxic tolerance. Knockdown of HIF-1alpha in melanoma cells resulted in decreased cell survival under hypoxic conditions. Pharmacologic inhibition of BRAF by BAY 43-9006 also resulted in decreased HIF-1alpha expression. Although HIF-1alpha translational rate was not changed, the protein was less stable in BRAF knockdown cells. In additional, von Hippel-Lindau protein expression was significantly increased in BRAF knockdown cells. Our data show for the first time that BRAF(V600E) mutation increases HIF-1alpha expression and melanoma cell survival under hypoxic conditions and suggest that effects of the oncogenic V600E BRAF mutation may be partially mediated through the HIF-1alpha pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409425     DOI: 10.1158/0008-5472.CAN-06-3312

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.

Authors:  Matthew L Fisher; Gautam Adhikary; Dan Grun; David M Kaetzel; Richard L Eckert
Journal:  Mol Carcinog       Date:  2015-12-23       Impact factor: 4.784

2.  Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs).

Authors:  Antônio Talvane Torres de Oliveira; Céline Pinheiro; Adhemar Longatto-Filho; Maria Jose Brito; Olga Martinho; Delcio Matos; André Lopes Carvalho; Vinícius Lima Vazquez; Thiago Buosi Silva; Cristovam Scapulatempo; Sarhan Sydney Saad; Rui Manuel Reis; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-01-27       Impact factor: 2.945

3.  Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer.

Authors:  Hirotoshi Kikuchi; Maria S Pino; Min Zeng; Senji Shirasawa; Daniel C Chung
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

4.  The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.

Authors:  Céline Pinheiro; Vera Miranda-Gonçalves; Adhemar Longatto-Filho; Anna L S A Vicente; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Ricardo F A Costa; Cristiano R Viana; Rui M Reis; Fátima Baltazar; Vinicius L Vazquez
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

5.  Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.

Authors:  Alessia Bottos; Miriam Martini; Federica Di Nicolantonio; Valentina Comunanza; Federica Maione; Alberto Minassi; Giovanni Appendino; Federico Bussolino; Alberto Bardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

Review 6.  Overcoming resistance to BRAF inhibitors.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Ann Transl Med       Date:  2017-10

7.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Authors:  Hong Yu; Ronan McDaid; John Lee; Patricia Possik; Ling Li; Suresh M Kumar; David E Elder; Patricia Van Belle; Phyllis Gimotty; Matt Guerra; Rachel Hammond; Katharine L Nathanson; Maria Dalla Palma; Meenhard Herlyn; Xiaowei Xu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 8.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

9.  Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.

Authors:  S M Kumar; J Dai; S Li; R Yang; H Yu; K L Nathanson; S Liu; H Zhou; J Guo; X Xu
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

10.  Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas.

Authors:  N Burrows; J Resch; R L Cowen; R von Wasielewski; C Hoang-Vu; C M West; K J Williams; G Brabant
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.